Molecular signatures of a disturbed nasal barrier function in the primary tissue of Wegener's granulomatosis

Mucosal Immunology

Volumn 4, Issue 5, 2011, Pages 564-573

  Laudien, M ^a   Hasler R ^a   Wohlers, J ^a   Bock J ^a   Lipinski, S ^a   Bremer, L ^a   Podschun, R ^b   Ambrosch, P ^a   Lamprecht, P ^c   Rosenstiel, P ^a   Till, A ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 1; CD36 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 27; LYSOZYME; MESSENGER RNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 2; PSORIASIN; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC CODE; GENETIC SELECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NOSE MUCOSA; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION REGULATION; WEGENER GRANULOMATOSIS;

EID: 84860390550     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.9     Document Type: Article

References (56)

1. Reinhold-Keller, E., Herlyn, K., Wagner-Bastmeyer, R. & Gross, W. L. Stable incidence of primary systemic vasculitides over five years: results from the German Vasculitis Register. Arthritis Rheum. 53, 93-99 (2005). (Pubitemid 40216357)
2. Lamprecht, P. & Gross, W. L. Current knowledge on cellular interactions in the WG-granuloma. Clin. Exp. Rheumatol. 25, S49-S51 (2007). (Pubitemid 46656599)
3. Laudien, M., Ambrosch, P., Till, A., Podschun, R. & Lamprecht, P. [Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement]. Z. Rheumatol. 67, 397-406 (2008).
4. Wegener, F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr. Pathol. Anatom. 102, 36-68 (1939).
5. Laudien, M. et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin. Exp. Rheumatol. 28, 51-55 (2010).
6. Popa, E. R. et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1029-1033 (2007). (Pubitemid 47062516)
7. Stegeman, C. A. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12-17 (1994). (Pubitemid 24011495)
8. van Putten, J. W., van Haren, E. H. & Lammers, J. W. Association between Wegener's granulomatosis and Staphylococcus aureus infection? Eur. Respir. J. 9, 1955-1957 (1996). (Pubitemid 26294771)
9. Popa, E. R., Stegeman, C. A., Kallenberg, C. G. & Tervaert, J. W. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res. 4, 77-79 (2002).
10. Jagiello, P., Gross, W. L. & Epplen, J. T. Complex genetics of Wegener granulomatosis. Autoimmun. Rev. 4, 42-47 (2005). (Pubitemid 40126371)
11. Schreiber, S., Rosenstiel, P., Albrecht, M., Hampe, J. & Krawczak, M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat. Rev. Genet. 6, 376-388 (2005). (Pubitemid 40577181)
12. Swidsinski, A. et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122, 44-54 (2002). (Pubitemid 34049193)
13. Mayet, W. J., Marker-Hermann, E., Schlaak, J. & Meyer zum Buschenfelde, K. H. Irregular cytokine pattern of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand. J. Immunol. 49, 585-594 (1999). (Pubitemid 29292520)
14. Israel, H. L. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch. Intern. Med. 148, 2293-2295 (1988).
15. Rasmussen, N., Petersen, J., Remvig, L. & Andersen, V. Treatment of Wegener's granulomatosis with trimethoprim-sulfamethoxazole. APMIS Suppl. 19, 61-62 (1990).
16. Rusterholz, D. & Schlegel, C. [Infectious aspects of Wegener's granulomatosis]. Schweiz. Med. Wochenschr. (Suppl 125), 41S-43S (2000).
17. Stegeman, C. A., Tervaert, J. W., De Jong, P. E., Kallenberg, C. G., & Dutch Co-Trimoxazole Wegener Study Group Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16-20 (1996). (Pubitemid 26230808)
18. De Groot, K. et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate vs. trimethoprim/sulfamethoxazole. Arthritis Rheum. 39, 2052-2061 (1996).
19. Reinhold-Keller, E. et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 89, 15-23 (1996). (Pubitemid 26023960)
20. Vaudaux, P., Kelley, W. L. & Lew, D. P. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin. Infect. Dis. 43, 968-970 (2006). (Pubitemid 44631094)
21. DeRemee, R. A. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum. 31, 1068-1074 (1988).
22. Bernstein, J. M. Mucosal immunology of the upper respiratory tract. Respiration 59 (Suppl 3), 3-13 (1992).
23. Ullrich, S. et al. Severe impaired respiratory ciliary function in Wegener granulomatosis. Ann. Rheum. Dis. 68, 1067-1071 (2009).
24. Peyrin-Biroulet, L. et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc. Natl Acad. Sci. USA 107, 8772-8777 (2010).
25. Costello, C. M. et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2, e199 (2005).
26. Abdulahad, W. H., Stegeman, C. A., Limburg, P. C. & Kallenberg, C. G. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 58, 2196-2205 (2008). (Pubitemid 351988114)
27. Csernok, E. et al. Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin. Exp. Immunol. 105, 104-111 (1996). (Pubitemid 26231832)
28. Muller, A. & Lamprecht, P. [Interleukin-17 in chronic inflammatory and autoimmune diseases: rheumatoid arthritis, Crohn's disease and Wegener's granulomatosis]. Z. Rheumatol. 67, 72-74 (2008).
29. Kozak, M. Some thoughts about translational regulation: forward and backward glances. J. Cell Biochem. 102, 280-290 (2007). (Pubitemid 47519402)
30. Holmes, M. V. et al. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 4, e7960 (2009).
31. Verweij, C. L. Transcript profiling towards personalised medicine in rheumatoid arthritis. Neth. J. Med. 67, 364-371 (2009).
32. Hasler, R. et al. Genetic control of global gene expression levels in the intestinal mucosa: a human twin study. Physiol. Genomics 38, 73-79 (2009).
33. Chen, X. et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J. Dermatol. Sci. 40, 123-132 (2005). (Pubitemid 41446209)
34. Morrison, G., Kilanowski, F., Davidson, D. & Dorin, J. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect. Immun. 70, 3053-3060 (2002). (Pubitemid 34564166)
35. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780-13785 (2007). (Pubitemid 350003397)
36. Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205-211 (2006). (Pubitemid 43117279)
37. Ott, S. J. et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53, 685-693 (2004). (Pubitemid 38561447)
38. Wieczorek, S., Holle, J. U. & Epplen, J. T. Recent progress in the genetics of Wegener's granulomatosis and Churg-Strauss syndrome. Curr. Opin. Rheumatol. 22, 8-14 (2010).
39. Wieczorek, S. et al. A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis. J. Mol. Med. 88, 413-421 (2010).
40. Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005). (Pubitemid 40388058)
41. Wilson, D. et al. Identifying infection-associated genes of Candida albicans in the postgenomic era. FEMS Yeast Res. 9, 688-700 (2009).
42. Stefaniuk, P., Cianciara, J. & Wiercinska-Drapalo, A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 16, 418-424 (2010).
43. Machugh, D. E. et al. Gene expression profiling of the host response to Mycobacterium bovis infection in cattle. Transbound. Emerg. Dis. 56, 204-214 (2009).
44. Handkiewicz-Junak, D., Czarniecka, A. & Jarzab, B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol. Cell Endocrinol. 322, 8-28 (2010).
45. Eddy, J. A., Sung, J., Geman, D. & Price, N. D. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol. Cancer Res. Treat. 9, 149-159 (2010).
46. Hellmich, B. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605-617 (2007). (Pubitemid 46707128)
47. Luqmani, R. A. Assessing disease activity in the systemic vasculitides. Curr. Opin. Rheumatol. 14, 23-28 (2002). (Pubitemid 34059885)
48. DeRemee, R. A., McDonald, T. J., Harrison, E. G. Jr. & Coles, D. T. Wegener's granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin. Proc. 51, 777-781 (1976). (Pubitemid 8014863)
49. Paulsen, J. I. & Rudert, H. [Manifestations of primary vasculitis in the ENT region]. Z. Rheumatol. 60, 219-225 (2001). (Pubitemid 32831645)
50. Reinhold-Keller, E. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 43, 1021-1032 (2000). (Pubitemid 30368179)
51. Benninger, M. S. et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol. Head Neck Surg. 129, S1-S32 (2003).
52. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001). (Pubitemid 34164012)
53. Benjamini, Y. & Hochberg, Y. A practical and powerful approach to multiple testing. J. Roy. Statist. Soc. 57, 289-300 (1995).
54. Westfall, P. H. & Young, S. Resampling-Based Multiple Testing (Wiley-Interscience, New York, 1993).
55. Bryborn, M., Mansson, A., Cardell, L. O. & Adner, M. Differentiated S100A7 expression in infected tonsils and tonsils from allergic individuals. FEMS Immunol. Med. Microbiol. 53, 413-420 (2008).
56. Claeys, S. et al. Human beta-defensins and toll-like receptors in the upper airway. Allergy 58, 748-753 (2003). (Pubitemid 36920464)